Privia Health Group (NASDAQ:PRVA – Get Free Report) and Pulmonx (NASDAQ:LUNG – Get Free Report) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations.
Institutional & Insider Ownership
94.5% of Privia Health Group shares are owned by institutional investors. Comparatively, 91.0% of Pulmonx shares are owned by institutional investors. 10.7% of Privia Health Group shares are owned by insiders. Comparatively, 6.8% of Pulmonx shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Analyst Recommendations
This is a summary of recent ratings and recommmendations for Privia Health Group and Pulmonx, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Privia Health Group | 0 | 3 | 13 | 0 | 2.81 |
| Pulmonx | 1 | 4 | 5 | 0 | 2.40 |
Profitability
This table compares Privia Health Group and Pulmonx’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Privia Health Group | 0.89% | 2.52% | 1.47% |
| Pulmonx | -61.91% | -77.58% | -37.90% |
Volatility and Risk
Privia Health Group has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500. Comparatively, Pulmonx has a beta of 0.1, suggesting that its share price is 90% less volatile than the S&P 500.
Valuation & Earnings
This table compares Privia Health Group and Pulmonx”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Privia Health Group | $1.74 billion | 1.62 | $14.39 million | $0.13 | 175.85 |
| Pulmonx | $91.66 million | 0.79 | -$56.39 million | ($1.41) | -1.24 |
Privia Health Group has higher revenue and earnings than Pulmonx. Pulmonx is trading at a lower price-to-earnings ratio than Privia Health Group, indicating that it is currently the more affordable of the two stocks.
Summary
Privia Health Group beats Pulmonx on 13 of the 14 factors compared between the two stocks.
About Privia Health Group
Privia Health Group, Inc. operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings. It offers technology and population health tools to enhance independent providers' workflows; management services organization that enable providers to focus on their patients by reducing administrative work; single-TIN medical group that facilitates payer negotiation, clinical integration and alignment of financial incentives; accountable care organization, which engage patients, reduce inappropriate utilization, and enhance coordination and patient quality metrics to drive value-based care; and network for purchasers and payers that enable providers to connect with new patient populations and create custom contracts. The company was founded in 2007 and is headquartered in Arlington, Virginia.
About Pulmonx
Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
Receive News & Ratings for Privia Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Privia Health Group and related companies with MarketBeat.com's FREE daily email newsletter.
